Comparison Of Clinical Efficacy And Survival Rate Of Neoadjuvant Chemotherapy In Advanced Ovarian Cancer

Objective: To explore the effect of neoadjuvant chemotherapy combined with interval debulking surgery on the clinical efficacy and survival situation of patients with advanced ovarian cancer.Methods: Retrospectively reviewed the clinical and follow-up data of patients with 92 advanced ovarian cancer(FIGO stage III-IV)admitted to the gynecological department of the First Hospital of Lanzhou University from January 2007 to January 2015 and confirmed by our pathology department.The patients were divided into two groups: NACT-IDS(30 patients),PDS(62 patients).The clinical curative effect,survival situations,and degrees of adverse reactions in the two groups were analyzed and compared.Results: 1.In those 92 patients,80 were older than 45,accounting for 86.9% of the total,this is basically consistent with epidemiological data;2.Age,FIGO stage,histological type,differentiation and chemotherapy regimen were not statistically significant with NACT efficacy(P > 0.05);3.Operation time:group NACT+IDS was 184.5±98.9 min,group PDS was 237.0±99.0 min.The difference between the two groups was statistically significant(P < 0.05);4.Ascites: group NACT+IDS was 631.0±206.5ml,group PDS was 1297.3±389.7ml,.The difference between the two groups was statistically significant(P < 0.05);5.Blood loss: group NACT+IDS was 291.7±168.2ml ml,group PDS was430.3±275.7 ml.The difference between the two groups was statistically significant(P < 0.05);6.The composition of the primary tumor size was statistically significant between the PDS group and the NACT+IDS group(P < 0.05);7.The total effective rate of group NACT+IDS was 56.7%(17/30),group PDS was 32.2%(20/62),NACT+IDS group was higher than PDS group,and the difference was statistically significant(P <0.05);8.In the NACT+IDS group,16(53.3%)of the 30 patients had surgical complications,and in the PDS group,34(54.8%)of the 62 patients had surgical complications.The former was slightly less than the latter,but the difference was not statistically significant(P >0.05).9.The 1-year survival rates in the NACT+IDS group and PDS group were 86.7% and 75.8%;3-year survival rates were 86.7% and 75.8%,the difference was not statistically significant(P > 0.05).Conclusions: Neoadjuvant chemotherapy before surgery for patients with advanced ovarian cancer can reduce the tumor volume,control ascites,shorten the operation time,reduce intraoperative blood loss,improve the general condition,and create surgical treatment for patients who have missed the best surgery,However,it has no obvious advantage in improving the postoperative survival rate.